Carcinogenic Effects of Exogenous and Endogenous Glucagon-Like Peptide-2 in Azoxymethane-Treated Mice

  • Roman Iakoubov
    Department of Physiology (R.I., L.M.L., S.T., P.L.B.), University of Toronto, Toronto, Ontario, Canada M5S 1A8
  • Lina M. Lauffer
    Department of Physiology (R.I., L.M.L., S.T., P.L.B.), University of Toronto, Toronto, Ontario, Canada M5S 1A8
  • Shivangi Trivedi
    Department of Physiology (R.I., L.M.L., S.T., P.L.B.), University of Toronto, Toronto, Ontario, Canada M5S 1A8
  • Young-In J. Kim
    Department of Nutritional Sciences (Y.-I.J.K.), University of Toronto, Toronto, Ontario, Canada M5S 1A8
  • Patricia L. Brubaker
    Department of Physiology (R.I., L.M.L., S.T., P.L.B.), University of Toronto, Toronto, Ontario, Canada M5S 1A8

抄録

<jats:title>Abstract</jats:title> <jats:p>Glucagon-like peptide-2 (GLP-2) is a nutrient-dependent intestinotropic hormone that promotes intestinal growth, via increased intestinal proliferation and decreased apoptosis, as well as increases in nutrient absorption and barrier function. The long-acting analog h(Gly2)GLP-2[1-33] is currently being tested for treatment of short bowel syndrome and Crohn’s disease. However, the role of GLP-2 in colon carcinogenesis is controversial. To assess the intestinotropic effects of exogenous and endogenous GLP-2, C57BL6/J mice were injected with 1μg h(Gly2)GLP-2[1-33]; 30 or 60 ng hGLP-2[3-33], a GLP-2 receptor antagonist; or PBS (4 wk, twice a day, sc). Chronic h(Gly2)GLP-2[1-33] increased small intestinal weight/body weight (P &lt; 0.001), villus height (P &lt; 0.001), crypt depth (P &lt; 0.001), and crypt cell proliferation, as measured by expression of the proliferative marker Ki67 (P &lt; 0.05–0.01). In contrast, chronic hGLP-2[3-33] decreased small intestinal weight/body weight (P &lt; 0.05) and colon weight/body weight (P &lt; 0.05). To assess the carcinogenic effects of endogenous and exogenous GLP-2, separate mice were injected with azoxymethane (10 mg/kg, 4 wk, every 7 d, ip), followed by 1.5 μg h(Gly2)GLP-2[1-33], 30 ng hGLP-2[3-33], or PBS (4 wk, twice a day, sc) 2 or 12 wk thereafter. At 10 or 46 wk after azoxymethane treatment, the numbers of aberrant crypt foci increased with h(Gly2)GLP-2[1-33] (P &lt; 0.001) and decreased with hGLP-2[3-33] (P &lt; 0.01–0.05) treatment. Furthermore, mucin-depleted aberrant foci, consistent with progressive dysplasia, were almost exclusively present in h(Gly2)GLP-2[1-33]-treated mice (P &lt; 0.01–0.001). Additionally, adenocarcinomas developed in h(Gly2)GLP-2[1-33]-treated mice but not in those receiving hGLP-2[3-33] or PBS. Taken together, these studies indicate that chronic treatment with GLP-2 enhances colon carcinogenesis, whereas antagonism of the GLP-2 receptor decreases dysplasia, with possible implications for human therapy.</jats:p>

収録刊行物

  • Endocrinology

    Endocrinology 150 (9), 4033-4043, 2009-06-04

    The Endocrine Society

被引用文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ